(Q44747076)

5 December 2017

title

Risks and benefits of long-term bisphosphonate therapy (English)

1 reference

5 December 2017

Ginelle A Schmidt

1

1 reference

5 December 2017

Kathleen E Horner

2

1 reference

5 December 2017

Deanna L McDanel

3

1 reference

5 December 2017

Mary B Ross

4

1 reference

5 December 2017

Kevin G Moores

5

1 reference

5 December 2017

publication date

1 June 2010

1 reference

American Journal of Health-System Pharmacy

5 December 2017

published in

1 reference

5 December 2017

volume

67

1 reference

5 December 2017

issue

12

1 reference

5 December 2017

page(s)

994-1001

1 reference

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Risedronate reduces the risk of first vertebral fracture in osteoporotic women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Transmission of human herpesvirus 8 by blood transfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Zoledronic acid and clinical fractures and mortality after hip fracture

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Bisphosphonates: mechanism of action and role in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Bone safety of long-term bisphosphonate treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Ten years' experience with alendronate for osteoporosis in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Treatment of osteoporosis: all the questions we still cannot answer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

A rational approach to evidence gaps in the management of osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Severely suppressed bone turnover: a potential complication of alendronate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Low-energy femoral shaft fractures associated with alendronate use.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Severely suppressed bone turnover and atypical skeletal fragility

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Case reports: two femoral insufficiency fractures after long-term alendronate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Bone quality: where do we go from here?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Use of Alendronate After 5 Years of Treatment—Reply

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090506

31 March 2020

Identifiers

DOI

10.2146/AJHP090506

1 reference

5 December 2017

1 reference